Lexicon Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (LXRX)

Q: What does CUSIP 528872302 represent in this 13F holders report?

CUSIP 528872302 is the security identifier for LXRX - Lexicon Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held LXRX - Lexicon Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share in Q2 2024?

121 institutional investors reported LXRX - Lexicon Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share for Q2 2024. Use the holders table for investor-level position and value details.

CUSIP: 528872302

Q2 2024 13F Holders as of 30 Jun 2024

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 444,558,533
Total 13F shares: 278,343,151
Share change: +106,509,891
Total reported value: $467,625,172
Put/Call ratio: 46%
Price per share: $1.68
Number of holders: 121
Value change: +$175,856,984
Number of buys: 71
Number of sells: 36

Quarterly Holders Quick Answers

What is CUSIP 528872302?
CUSIP 528872302 identifies LXRX - Lexicon Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2024
Previous quarter: Q1 2024

Recent filing periods for CUSIP 528872302:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of LXRX - Lexicon Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Artal Group S.A.	13F	Company	26%	117,553,284	$282,127,882	—	31 Mar 2024	13F
FMR LLC	13F	Company	3.1%	13,894,062	$33,345,749	—	31 Mar 2024	13F
BlackRock Finance, Inc.	13F	Company	1.7%	7,693,277	$18,463,864	—	31 Mar 2024	13F
VANGUARD GROUP INC	13F	Company	1.4%	6,401,225	$15,362,940	—	31 Mar 2024	13F
ORBIMED ADVISORS LLC	13F	Company	0.8%	3,542,000	$8,500,800	—	31 Mar 2024	13F
Invus US Partners LLC	3/4/5	Director, 10%+ Owner	— class O/S missing	5,782,749	$6,090,969	—	05 Aug 2022	3/4/5
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.54%	2,389,137	$5,734,687	—	31 Mar 2024	13F
NEA Management Company, LLC	13F	Company	0.54%	2,382,286	$5,717,486	—	31 Mar 2024	13F
Schonfeld Strategic Advisors LLC	13F	Company	0.22%	960,150	$5,348,625	—	31 Mar 2024	13F
STATE STREET CORP	13F	Company	0.45%	1,987,510	$4,770,024	—	31 Mar 2024	13F
PINNACLE ASSOCIATES LTD	13F	Company	0.39%	1,747,830	$4,194,792	—	31 Mar 2024	13F
BVF INC/IL	13F	Company	0.38%	1,686,924	$4,048,618	—	31 Mar 2024	13F
Lonnel Coats	3/4/5	Chief Executive Officer, Director	— mixed-class rows	2,109,255 mixed-class rows	$3,507,748	—	28 Feb 2024	3/4/5
AMERIPRISE FINANCIAL INC	13F	Company	0.32%	1,417,950	$3,403,080	—	31 Mar 2024	13F
Cubist Systematic Strategies, LLC	13F	Company	0.32%	1,404,928	$3,371,827	—	31 Mar 2024	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.2%	881,123	$2,114,695	—	31 Mar 2024	13F
NORTHERN TRUST CORP	13F	Company	0.19%	866,556	$2,079,735	—	31 Mar 2024	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	0.15%	686,418	$1,647,403	—	31 Mar 2024	13F
Point72 Asset Management, L.P.	13F	Company	0.13%	584,386	$1,402,526	—	31 Mar 2024	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.12%	534,184	$1,282,042	—	31 Mar 2024	13F
Nuveen Asset Management, LLC	13F	Company	0.12%	524,177	$1,258,025	—	31 Mar 2024	13F
MARSHALL WACE, LLP	13F	Company	0.11%	499,172	$1,198,014	—	31 Mar 2024	13F
ExodusPoint Capital Management, LP	13F	Company	0.07%	319,058	$766,000	—	31 Mar 2024	13F
GSA CAPITAL PARTNERS LLP	13F	Company	0.07%	293,333	$704,000	—	31 Mar 2024	13F
VIRTUS ADVISERS, LLC	13F	Company	0.07%	293,092	$703,421	—	31 Mar 2024	13F
Bank of New York Mellon Corp	13F	Company	0.07%	292,006	$700,815	—	31 Mar 2024	13F
JANE STREET GROUP, LLC	13F	Company	0.06%	281,588	$675,811	—	31 Mar 2024	13F
BOULDER HILL CAPITAL MANAGEMENT LP	13F	Company	0.06%	256,400	$615,360	—	31 Mar 2024	13F
B. Kassler Taub	3/4/5	SVP, Regulatory & QA	— mixed-class rows	431,995 mixed-class rows	$597,845	—	28 Feb 2024	3/4/5
MORGAN STANLEY	13F	Company	0.05%	244,209	$586,101	—	31 Mar 2024	13F
ALLIANCEBERNSTEIN L.P.	13F	Company	0.05%	219,941	$527,858	—	31 Mar 2024	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.04%	189,431	$454,634	—	31 Mar 2024	13F
UBS Group AG	13F	Company	0.04%	166,961	$400,707	—	31 Mar 2024	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.04%	156,214	$374,914	—	31 Mar 2024	13F
RHUMBLINE ADVISERS	13F	Company	0.03%	134,845	$323,623	—	31 Mar 2024	13F
CITADEL ADVISORS LLC	13F	Company	0.03%	134,477	$322,745	—	31 Mar 2024	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	0.02%	105,315	$253,000	—	31 Mar 2024	13F
Thomas Garner	3/4/5	SVP, Chief Commercial Officer	— mixed-class rows	454,260 mixed-class rows	$239,236	—	08 Feb 2024	3/4/5
COMMONWEALTH EQUITY SERVICES, LLC	13F	Company	0.02%	95,184	$228,000	—	31 Mar 2024	13F
Lombard Odier SCmA Compagnie	13F	Individual	0.02%	94,000	$225,600	—	31 Mar 2024	13F
Robert J. Lefkowitz MD	3/4/5	Director	— mixed-class rows	130,080 mixed-class rows	$223,156	—	13 May 2024	3/4/5
JPMORGAN CHASE & CO	13F	Company	0.02%	90,136	$216,326	—	31 Mar 2024	13F
LPL Financial LLC	13F	Company	0.02%	89,963	$215,911	—	31 Mar 2024	13F
NATIXIS ADVISORS, LLC	13F	Company	0.02%	86,094	$207,000	—	31 Mar 2024	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.02%	85,872	$206,092	—	31 Mar 2024	13F
BARCLAYS PLC	13F	Company	0.01%	64,619	$155,085	—	31 Mar 2024	13F
Pathstone Holdings, LLC	13F	Company	0.01%	62,725	$150,540	—	31 Mar 2024	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0.01%	59,378	$142,507	—	31 Mar 2024	13F
STIFEL FINANCIAL CORP	13F	Company	0.01%	52,174	$125,217	—	31 Mar 2024	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.01%	49,943	$119,863	—	31 Mar 2024	13F

Institutional Holders of Lexicon Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (LXRX) as of Q2 2024

As of 30 Jun 2024, Lexicon Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (LXRX) was held by 121 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 278,343,151 shares. The largest 10 holders included Artal Group S.A., FMR LLC, BlackRock Inc., BRAIDWELL LP, VANGUARD GROUP INC, ORBIMED ADVISORS LLC, Point72 Asset Management, L.P., GEODE CAPITAL MANAGEMENT, LLC, CITADEL ADVISORS LLC, and NEA Management Company, LLC. This page lists 121 institutional shareholders reporting positions in this security for the Q2 2024 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2024 vs Q1 2024 Across Filers

Q1 2024 holders

114

Q2 2024 holders

121

Holder diff

Investor	Q1 2024 Shares	Q2 2024 Shares	Share Diff	Share Chg %	Q1 2024 Value $	Q2 2024 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.